Name
NMNAT1 Human, Active
Cat. No.
MAG-4092
Tag/Conjugates
His
Source
Escherichia Coli.
Shipped
Shipped with Ice Packs
Description
NMNAT1 Recombinant Human produced in E.Coli is a single,non-glycosylated polypeptide chain containing 315 amino acids (1-279 a.a.) and having a molecular mass of 36 kDa.
Introduction
NMNAT1 enzyme is vital for NAD biosynthesis, catalyzing the condensation of nicotinamide mononucleotide (NMN) or nicotinic acid mononucleotide (NaMN) with the AMP moiety of ATP to form NAD or NaAD. NMNAT1 is widely expressed with high levels in skeletal muscle, heart, liver and kidney. This protein appears to have the ability to protect against axonal degeneration following mechanical or toxic insults.
Purification Method
/
Physical Appearance
Sterile filtered colorless solution.
Formulation
The NMNAT1 solution (1mg/ml) contains 20mM Tris-HCl
buffer (pH8.0), 20% glycerol, 0.1M NaCl, 1mM DTT and 1mM EDTA.
Stability
Store at 4°C if entire vial will be used within 2-4
weeks.
Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier
protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Biological Activity
Specific activity is > 7,000 pmol/min/ug, and was
obtained by measuring the beta-NAD from nicotinamide mononucleotide and ATP per
minute at pH 8.0 at 37C.
Safety Data Sheet
SDS
Usage
Mabioway's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Synonyms
NMNAT, NMNAT1, PNAT1, Nicotinamide mononucleotide adenylyltransferase 1, NMN adenylyltransferase 1, Nicotinate-nucleotide adenylyltransferase 1, NaMN adenylyltransferase 1, EC=2.7.7.1, EC=2.7.7.18.
Amino acid sequence
MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGS MENS EKTEVVLLAC GSFNPITNMH LRLFELAKDY MNGTGRYTVV KGIISPVGDA YKKKGLIPAY HRVIMAELAT KNSKWVEVDT WESLQKEWKE TLKVLRHHQE KLEASDCDHQ QNSPTLERPG RKRKWTETQD SSQKKSLEPK TKAVPKVKLL CGADLLESFA VPNLWKSEDI TQIVANYGLI CVTRAGNDAQ KFIYESDVLW KHRSNIHVVN EWIANDISST KIRRALRRGQSIRYLVPDLV QEYIEKHNLY SSESEDRNAG VILAPLQRNT AEAKT.
Background
/
